Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00006227 · OUTCOME

Probability of Complete Clinical Response

Paclitaxel in Treating Patients With Ovarian Stromal Cancer · Source last updated 2020-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
80% Confidence Interval
Time frame
Up to 5 years

What was measured

The probability of complete clinical response (i.e. proportion of participants) (assessed using GOG RECIST criteria) of paclitaxel as second line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma

Analysis population: Eligible and evaluable

Groups in this outcome

Treatment (Paclitaxel)

Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Paclitaxel)31

Reported measurements

Source class 1
Values in Percentage of Participants · Interval/dispersion: 80% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Paclitaxel)3.2Not reported0.7415.30Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.74
        upper Limit
        15.30
        value
        3.2
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
The probability of complete clinical response (i.e. proportion of participants) (assessed using GOG RECIST criteria) of paclitaxel as second line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma
dispersion Type
80% Confidence Interval
groups
  1. description
    Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Paclitaxel: Given IV
    id
    OG000
    title
    Treatment (Paclitaxel)
param Type
NUMBER
population Description
Eligible and evaluable
reporting Status
POSTED
time Frame
Up to 5 years
title
Probability of Complete Clinical Response
type
PRIMARY
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice